Conversions between monotherapies in epilepsy: Expert consensus

Epilepsy and Behavior

Volumn 11, Issue 2, 2007, Pages 222-234

  St Louis, Erik K ^a   Gidal, Barry E ^b   Henry, Thomas R ^c   Kaydanova, Yevgenya ^d   Krumholz, Allan ^e   McCabe, Paul H ^f   Montouris, Georgia D ^g   Rosenfeld, William E ^h   Smith, Brien J ⁱ   Stern, John M ^j   Waterhouse, Elizabeth J ^k   Schulz, Richard M ^l   Garnett, William R ^k   Bramley, Thomas ^m  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ST LUKE S HOSPITAL   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF SOUTH CAROLINA   (United States)

^m XCENDA   (United States)

more..

Author keywords

Antiepileptic drugs; Conversion; Delphi Technique; Epilepsy; Expert opinion; Monotherapy; Polytherapy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; CONSENSUS DEVELOPMENT; DRIVING ABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; RECOMMENDED DRUG DOSE; SEIZURE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; CONSENSUS; EPILEPSY; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED;

EID: 34548043466     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.04.007     Document Type: Article

References (47)

1. LaRoche S.M., and Helmers S.L. The new antiepileptic drugs: scientific review. JAMA 291 (2004) 605-614
2. Gidal B.E., and Garnett W.R. Epilepsy. In: DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., and Posey L.M. (Eds). Pharmacotherapy: a pathophysiologic approach. 6th ed. (2005), McGraw-Hill, New York 1023-1048
3. Kwan P., and Brodie M. Effectiveness of first antiepileptic drug. Epilepsia 42 (2001) 1255-1260
4. Brodie M.J., Overstall P.W., Giorgi L., et al. Multicenter, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 37 (1999) 81-87
5. Steiner T.J., Dellaportas C.I., Findley L.J., et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 40 (1999) 601-607
6. Dam M., Ekberg R., Loyning Y., et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3 (1989) 70-76
7. Bill P.A., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 26 (1997) 451-460
8. Chadwick D.W., Anhut H., Greiner M.J., et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 51 (1998) 1282-1288
9. Privitera M.D., Brodie M.J., Mattson R.H., et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107 (2003) 165-175
10. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64 (2005) 1888-1893
11. Beydoun A., Fischer J., Labar D.R., et al. For the US Gabapentin Study Group 82/83. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology 49 (1997) 746-752
12. Beydoun A., Sachdeo R.C., D'Souza J., et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 54 (2000) 2245-2251
13. Cramer J.A., Hammer A.E., and Kustra R.P. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 5 (2004) 224-230
14. Faught E., Sachdeo R.C., Remler M.P., et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 43 (1993) 688-692
15. Fakhoury T.A., Hammer A.E., Vuong A., et al. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy Behav 5 (2004) 532-538
16. Gilliam F., Vasquez B., Sackellares J.C., et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 51 (1998) 1018-1025
17. Sachdeo R., Kramer L.D., Rosenberg A., et al. Felbamate monotherapy: controlled trial in patients with partial-onset seizures. Ann Neurol 32 (1992) 386-392
18. Sachdeo R., Reife R.A., Lim P., et al. Topiramate monotherapy for partial-onset seizures. Epilepsia 38 (1997) 294-300
19. Sachdeo R., Beydoun A., Schachter S., et al. Oxcarbazepine (trileptal) as monotherapy in patients with partial seizures. Neurology 57 (2001) 864-871
20. Schachter S.C. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 36 Suppl. 6 (1995) S2-S6
21. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord 5 (2003) 125-132
22. Gilliam F.G. Limitation of monotherapy trials in epilepsy. Neurology 60 (2003) S26-S30
23. Naritoku D.K., Hulihan J.F., Schwarzman L.K., Kamin M., and Olson W.H. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Ann Pharmacother 39 (2005) 418-423
24. Arroyo S., and Perucca E. Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy Behav 4 (2003) 457-463
25. Waltz C.F., Strickland O.L., and Lenz E.R. Measurement in nursing research (1991), Davis, Philadelphia
26. Clauser J.K., and Weir S.M. Intelligence research methodology (1976), Defense Intelligence College, Washington, DC p. 302-3
27. Brook R., Chassin M., Fink A., Solomon D.H., Kosecoff J., and Park R.E. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 2 (1986) 53-63
28. Wyrich K.W., Spertus J.A., Kroenke K., Tierney W.M., Babu A.N., and Wolinsky F.D. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J 147 (2004) 615-622
29. Ficker D.M., Privitera M., Krauss G., Kanner A., Moore J.L., and Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65 (2005) 593-595
30. McCabe P.H., Michel N.C., McNew C.D., and Lehman E.B. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long term follow-up. Epilepsy Behav 8 (2006) 601-605
31. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40 (1999) 985-991
32. Hirsch L.J., Weintraub D.B., Buchsbaum R., et al. Predictors of lamotrigine-associated rash. Epilepsia 47 (2006) 318-322
33. Biton V., Sackellares J.C., Vuong A., Hammer A.E., Barrett P.S., and Messenheimer J.A. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65 (2005) 1737-1743
34. Privitera M.D. Clinical rules for phenytoin dosing. Ann Pharmacother 27 (1993) 1169-1173
35. Ferendelli J.A. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 42 Suppl. 4 (2001) 28-30
36. Genton P., Guerrini R., and Perucca E. Tiagabine in clinical practice. Epilepsia 42 Suppl. 3 (2001) 42-45
37. Vasquez B. Monotherapy in epilepsy. Arch Neurol 61 (2004) 1361-1365
38. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs: I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
39. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., and Meencke H.J. Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
40. Yagi K. Overview of Japanese experience-controlled and uncontrolled trials. Seizure 13 Suppl. 1 (2004) S11-S15 discussion S16
41. Karceski S. Treatment of epilepsy in adults: expert opinion. Epilepsy Behav 7 (2005) S1-S64
42. Willmore L. Care of adults with epilepsy in the United States. Neurology 48 Suppl. 8 (1997) S39-S43
43. Cloyd J.C., and Remmel R.P. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 20 8, Pt. 2 (2000) 139S-151S
44. Pataslos P.N., Froscher W., Pisani F., and van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 43 (2002) 365-385
45. Pataslos P.N., and Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2 (2003) 473-481
46. Anderson G.D., Gidal B.E., Messenheimer J.A., and Gilliam F.G. Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 49 (2002) 211-217
47. Gilliam F., Kuzniecky R., Faught E., Black L., Carpenter G., and Schrodt R. Patient-validated content of epilepsy-specific quality of life measurement. Epilepsia 38 (1997) 233-236